Travoprost Intraocular Implant in Conjunction With Cataract Surgery
Trial details
- Registry ID
- NCT06061718
- Phase
- Phase 3
The FDA approved iDose TR (travoprost intraocular implant) on 13 Dec 2023.
Drug identity checked against registry records
Also recorded as travoprost intraocular implant
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Travoprost Intraocular Implant in Conjunction With Cataract SurgeryNCT06061718 | Glaukos Corporation | Phase 3 | Unknown | 2024-03-18Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2023-12-13Day | iDose TR | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA218010", "applicant_as_listed_by_fda": "GLAUKOS", "brand_names": ["IDOSE TR"], "active_ingredients": ["TRAVOPROST"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20231213", "matched_on": "drug name equals FDA brand name"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |